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AbSTrACT 
Aim To canvass the UK pathology community to 
ascertain current levels of digital pathology usage in 
clinical and academic histopathology departments, and 
prevalent attitudes to digital pathology.
Methods A 15-item survey was circulated to National 
Health Service and academic pathology departments 
across the UK using the SurveyMonkey online survey 
tool. Responses were sought at a departmental or 
institutional level. Where possible, departmental heads 
were approached and asked to complete the survey, 
or forward it to the most relevant individual in their 
department. Data were collected over a 6-month period 
from February to July 2017.
results 41 institutes from across the UK responded to 
the survey. 60% (23/39) of institutions had access to a 
digital pathology scanner, and 60% (24/40) had access 
to a digital pathology workstation. The most popular 
applications of digital pathology in current use were 
undergraduate and postgraduate teaching, research 
and quality assurance. Investigating the deployment of 
digital pathology in their department was identified as 
a high or highest priority by 58.5% of institutions, with 
improvements in efficiency, turnaround times, reporting 
times and collaboration in their institution anticipated by 
the respondents. Access to funding for initial hardware, 
software and staff outlay, pathologist training and 
guidance from the Royal College of Pathologists were 
identified as factors that could enable respondent 
institutions to increase their digital pathology usage.
Conclusion Interest in digital pathology adoption 
in the UK is high, with usage likely to increase in the 
coming years. In light of this, pathologists are seeking 
more guidance on safe usage.
InTroduCTIon
Digital pathology, the examination of digital slides 
on computer workstations, has long been recognised 
as an important tool in healthcare education and 
research.1 The evolution of whole slide imaging 
(WSI) hardware and software over the last decade, 
and the recent approval of the first WSI device for 
primary diagnosis in the USA have prompted a surge 
in interest in clinical digital pathology for primary 
and secondary diagnoses.2 Simultaneously, pathology 
services are under increasing pressure in terms of 
workload and work intensity, and it is thought 
that digital pathology might be part of the solution 
to emergent staffing issues.3 4 In light of this, the 
National Cancer Research Institute’s (NCRI) Cellular 
Molecular Pathology (CM-Path) initiative wanted to 
canvass the UK pathology community to ascertain 
current levels of digital pathology usage in clinical 
and academic histopathology departments.
MeThodS
A survey was developed by members of the tech-
nology and informatics workstream of the NCRI's 
CM-Path initiative. The survey comprised 15 items 
and assessed: (1) access to and ownership of digital 
pathology hardware; (2) current and predicted 
usage of digital pathology; and (3) prevailing atti-
tudes to digital pathology.
The survey was initially circulated to the whole 
CM-Path membership using the SurveyMonkey 
online survey tool (www. surveymonkey. com) with 
specific instructions for completion of forms. As the 
aim was to assess national trends in digital pathology 
uptake and attitudes, responses were sought at a 
departmental or institutional level. Where possible, 
departmental heads were approached and asked 
to complete the survey, or forward it to the most 
relevant individual in their department. Data were 
collected over a 6-month period from February to 
July 2017. Reminder emails were sent out during 
this period, and survey invitations were extended to 
academic and clinical pathology departments without 
a CM-Path member. Simple summary statistics were 
calculated for each questionnaire item. Not all ques-
tions were mandatory, and some questions allowed 
more than one response to be selected per respon-
dent, so denominators are shown for the results on a 
per question basis.
reSulTS
A total of 41 questionnaires were completed, 
representing 41 institutions in England, Wales and 
Scotland, with no duplications.
respondent demographics
Respondent demographics are shown in table 1. 
The majority of respondents represented National 
Health Service (NHS) clinical pathology depart-
ments (85%, 34/40), with the remaining 15% (6/40) 
of responses from university academic pathology 
units. Of the 34 clinical pathology departments that 
responded, 10 were based in district general hospi-
tals, and 24 in tertiary referral centres.
The clinical departments surveyed varied greatly 
in size, with the number of whole time equivalent 
consultants ranging from 4 to 47, and the estimated 
number of histopathology cases accessioned per 
year ranging from 2000 to 90 000.
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Access to and ownership of digital pathology hardware
60.0% (23/39) of participating institutions had access to a digital 
pathology scanner. Of these institutions, 34.8% (8/23) had an 
NHS-owned scanner, 43.5% (10/23) had a university-owned 
scanner and 21.7% (5/23) had access to a scanner owned by 
neither the NHS nor the university (see figure 1).
60.0% (24/40) of institutions had access to a digital pathology 
workstation, but only 46.2% (18/39) had access to a digital slide 
archive or library.
Current digital slide usage
58.8% (20/34) institutions reported that they do not currently 
produce any digital slides. Of the institutions that currently 
produce scanned slides, the annual total ranged from 50 slides 
to 30 000 slides.
The most popular applications of digital pathology in 
current use were undergraduate and postgraduate teaching, 
research and quality assurance. Experience with direct clin-
ical use of digital pathology was less widespread, but 31% 
of departments indicated they use digital slides for primary 
diagnosis and 36% for secondary diagnosis, in a proportion of 
cases (see figure 2).
Predicted digital slide usage
When asked to predict their institution’s projected usage of 
digital pathology in 1 year's time, an increased proportion of 
institutions predicted that digital slides would be used always or 
often for all digital slide use types (see figure 3).
Image analysis usage
41.0% of institutions (16/39) report that they currently use image 
analysis on digital slides, with immunoscoring, tumour environ-
ment assessment, basic measurements, tumour cell proportions 
and tumour segmentation given as examples of current usage.
Attitudes to digital pathology adoption and usage
The majority of departments (24/41, 58.5%) listed the investiga-
tion and use of digital pathology as a high or essential priority at 
their institution (see table 2).
When asked about the perceived benefits of digital pathology 
for their department, the majority of respondents agreed or 
strongly agreed that digital pathology would improve effi-
ciency, turnaround times, reporting times and collaboration 
in their institution (figure 4). Overall laboratory costs and 
safety were the only parameters that the majority of respon-
dents did not think would be improved by introducing digital 
pathology.
Respondents were next asked what they perceive to be the 
barriers to wider digital pathology adoption. 82.5% of respon-
dents agreed or strongly agreed that initial financial cost was a 
barrier to wider digital pathology usage at their institution, while 
only 15% agreed that safety concerns were impeding more wide-
spread use of digital slides (see figure 5).
Access to funding for initial hardware, software and staff 
outlay, training for pathologists and guidance from the Royal 
College of Pathologists were identified as factors that could 
enable respondent institutions to increase their digital pathology 
usage (see figure 6).
The following additional enabling factors were identified by 
respondents, and included as free text:
 ► Relevant UK data proving cost savings.
 ► Public Health England (PHE) approval for screening 
specimens.
Table 1 Respondent department characteristics
Type of institution % of responses responses, n
NHS—tertiary referral centre 60.0 24
NHS—district general hospital 25.0 10
University academic department 15.0 6
Total respondents 40
NHS, National Health Service.
Figure 1 Access to and ownership of digital pathology 
hardware. NHS, National Health Service.
Figure 2 Current usage of digital slides. MDT, multidisciplinary team 
meeting.
Figure 3 Projected usage of digital slides. MDT,  multidisciplinary 
team meeting. 
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 ► NHS England taking a clear and strong stance on digital 
pathology.
 ► Improved internet connections.
 ► Algorithms which improve reporting standards.
 ► A change in attitude from managers.
 ► Information technology infrastructure and personnel 
support.
dISCuSSIon
This NCRI’s CM-Path survey was the first attempt to gather 
national data on access to and usage of digital pathology in NHS 
and academic pathology departments in the UK. Sixty per cent 
of respondents had access to WSI scanners, with ownership 
of these devices split between the NHS and linked university 
departments. 41.2% of institutions reported that they currently 
actively produce digital slides in their department, with the most 
popular applications being for education, research and quality 
assurance purposes. Interestingly, 31% of respondents indicated 
that they currently use digital slides for primary diagnosis in a 
proportion of cases, and 36% use digital slides for secondary 
diagnosis, indicating that pathology departments are finding 
utility for the use of digital slides in certain aspects of clinical 
practice. Predictions for slide usage 1 year from now suggest 
more departments will be using digital pathology for diagnostic 
work, and for a greater proportion of cases in the near future.
One of the most interesting findings of the survey was 
reported level of prioritisation for digital pathology adop-
tion or investigation in the respondent institutions, with the 
majority of respondents listing it as a high or essential priority. 
Participants were optimistic that digital pathology could help 
improve diagnostic efficiency and turnaround time, and 97.6% 
agreed or strongly agreed that digital pathology could improve 
collaboration in their department. Interestingly, patient safety 
aspects of digital reporting were not emphasised by the survey 
respondents. Reducing the risk of patient/slide misidentification 
errors has been identified as one of the key benefits of digital 
pathology, taking pathology services one step closer to a paper-
free workflow.3
The most prevalent existing barrier to wider digital adoption 
for the survey respondents was financial cost to their depart-
ment. There have been long economic arguments in favour of 
the introduction of digital pathology (previously known as tele-
pathology) in many contexts3 but there is undoubtedly significant 
initial outlay, in terms of hardware and software, and ongoing 
training, maintenance and personnel costs. The time required 
to set up and deploy a system, train staff and ongoing staff time 
costs to run scanners was also implicated as a barrier for some 
departments. Clearly, these barriers are counterbalanced by the 
potential major benefits for diagnostic workflow, workload 
and workforce issues, and service quality and safety, outlined 
in a recent review.3 Little concern was expressed regarding the 
safety and accuracy of digital pathology diagnosis versus conven-
tional slide diagnosis, which may reflect the evolving evidence 
base for digital and glass slide diagnostic concordance. A recent 
systematic view of ref 5 found a glass:digital concordance rate 
of 92.4%, and a systematic analysis of glass:digital discordances 
found that the majority of these discordances were of little or no 
clinical significance.6
92.5% of respondents agreed or strongly agreed that funding 
was required to aid increased uptake of digital pathology in their 
institution, and 78% wanted guidance from the Royal College 
on digital pathology usage. Interestingly, more people identified 
Royal College guidance as a digital pathology enabler than a 
randomised controlled trial of digital pathology accuracy. A new 
Royal College of Pathologist’s guideline for digital pathology 
has been consulted on, and will shortly be published in its final 
Table 2 Prioritisation of digital pathology for institutions
digital pathology prioritisation % of responses responses, n
Not a priority 9.8 4
Low priority 15 6
Neutral 17 7
High priority 44 18
Essential priority 15 6
Total 41
Figure 4 Preferred factors to enable increased use of digital 
pathology.
Figure 5 Barriers to digital pathology in your institution. 
Figure 6 Perceived benefits of digital pathology.
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version,7 and may help more departments evaluate the oppor-
tunities and risks of digital pathology adoption in their depart-
ment. In free-text statements, respondents also indicated that a 
need for direction from NHS England and an approval from 
PHE were needed to enable them to move forward with digital 
pathology adoption.
The results of the survey suggest that interest in digital 
pathology adoption in the UK is high, and that an increasing 
proportion of pathological diagnosis will be made on digital 
slides in the immediate future. Furthermore, the recently 
published Life Sciences Industrial Strategy recognises the need 
for increased adoption of digital pathology within the NHS,8 
citing that digital pathology will allow the use of artificial intel-
ligence that could provide prognostic insights that are currently 
unavailable. To support this adoption, pathology departments 
would value clear guidelines and statements from key national 
healthcare, professional and regulatory bodies regarding their 
position on digital pathology in the clinic, and the necessary 
steps to take to ensure any adoption maintains or improves on 
current standards of quality and safety.
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Take home messages
 ► Access to, and usage of digital pathology hardware is 
predicted to grow rapidly in the next 12 months. 
 ► Digital pathology adoption has been reported as having 
a high or essential level of priority for the majority of 
responding departments. 
 ► Pathology departments are seeking clear guidelines and 
statements from national healthcare bodies to aid them in 
safe adoption of digital reporting technology. 
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